VEGFA and cancer: Recent data also demonstrated that concurrent neutralization of VEGFA and Ang-2 promotes the development and deployment of antitumor immunity in mouse models of cancer, expanding the rationale for trials combining Ang-2–directed therapy with checkpoint inhibitors [46].